(Q34767462)

4 August 2017

1 reference

title

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus (English)

1 reference

4 August 2017

0 references

1 reference

1

Antona J Wagstaff

1 reference

4 August 2017

Karen L Goa

2

1 reference

4 August 2017

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

62

1 reference

4 August 2017

12

1 reference

4 August 2017

1805-1837

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262120-00007

4 August 2017

0 references

1 reference

12 December 2020

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

12 December 2020

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

1 reference

12 December 2020

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

12 December 2020

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

12 December 2020

Novel euglycemic and hypolipidemic agents. 1

1 reference

12 December 2020

Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene

1 reference

12 December 2020

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

12 December 2020

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

12 December 2020

Rosiglitazone and type 2 diabetes mellitus

1 reference

12 December 2020

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

12 December 2020

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

1 reference

12 December 2020

Rosiglitazone and hepatic failure.

1 reference

12 December 2020

Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway

1 reference

12 December 2020

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes

1 reference

12 December 2020

The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus

1 reference

12 December 2020

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

12 December 2020

Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers

1 reference

12 December 2020

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

1 reference

12 December 2020

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes

1 reference

12 December 2020

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

1 reference

12 December 2020

A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.

1 reference

12 December 2020

Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats

1 reference

12 December 2020

Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin

1 reference

12 December 2020

Unraveling the mechanism of action of thiazolidinediones

1 reference

12 December 2020

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

1 reference

12 December 2020

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

12 December 2020

In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone

1 reference

12 December 2020

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.

1 reference

12 December 2020

Rosiglitazone toxicity

1 reference

12 December 2020

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

1 reference

12 December 2020

Differential activity of rosiglitazone enantiomers at PPAR gamma

1 reference

12 December 2020

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

12 December 2020

Peroxisome proliferator-activated receptors in the cardiovascular system

1 reference

12 December 2020

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

12 December 2020

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

1 reference

12 December 2020

A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999

1 reference

12 December 2020

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

12 December 2020

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

12 December 2020

Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics

1 reference

12 December 2020

Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.

1 reference

12 December 2020

Rosiglitazone approved for treatment of type 2 diabetes

1 reference

12 December 2020

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

1 reference

12 December 2020

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

12 December 2020

Recent developments and emerging therapies for type 2 diabetes mellitus

1 reference

12 December 2020

Insulin resistance: current therapeutic approaches.

1 reference

12 December 2020

Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.

1 reference

12 December 2020

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

12 December 2020

Clinical and economic impact of implementing a comprehensive diabetes management program in managed care

1 reference

12 December 2020

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

1 reference

12 December 2020

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

12 December 2020

Systemic exposure to rosiglitazone is unaltered by food

1 reference

12 December 2020

Hepatic failure in a patient taking rosiglitazone

1 reference

12 December 2020

Guidance on rosiglitazone for type 2 diabetes mellitus

1 reference

12 December 2020

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

12 December 2020

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus

1 reference

12 December 2020

A risk-benefit assessment of metformin in type 2 diabetes mellitus

1 reference

12 December 2020

Isolated elevation of alkaline phosphatase level associated with rosiglitazone

1 reference

12 December 2020

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

1 reference

12 December 2020

The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes

1 reference

12 December 2020

Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

1 reference

12 December 2020

Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans

1 reference

12 December 2020

Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.

1 reference

12 December 2020

Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma

1 reference

12 December 2020

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

1 reference

12 December 2020

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

12 December 2020

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

12 December 2020

Pulmonary edema associated with rosiglitazone and troglitazone

1 reference

12 December 2020

Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides

1 reference

12 December 2020

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

12 December 2020

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

12 December 2020

PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone

1 reference

12 December 2020

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

12 December 2020

Liver failure in a patient treated with long-term rosiglitazone therapy

1 reference

12 December 2020

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

12 December 2020

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

12 December 2020

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control

1 reference

12 December 2020

Rosiglitazone does not alter the pharmacokinetics of metformin.

1 reference

12 December 2020

Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation

1 reference

12 December 2020

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

12 December 2020

The effect of acarbose on the pharmacokinetics of rosiglitazone

1 reference

12 December 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

1 reference

12 December 2020

Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

Rosiglitazone for type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

1 reference

12 December 2020

Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression

1 reference

12 December 2020

Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.

1 reference

12 December 2020

Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene

1 reference

12 December 2020

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

1 reference

12 December 2020

10.2165/00003495-200262120-00007

Identifiers

DOI

1 reference

PubMed ID

12149047

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

12149047